Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03396887
Other study ID # UCD - Protocol 19/15
Secondary ID
Status Recruiting
Phase N/A
First received May 12, 2017
Last updated January 9, 2018
Start date May 1, 2017
Est. completion date September 30, 2018

Study information

Verified date November 2017
Source St Patrick's Hospital, Ireland
Contact Conor Farren, PhD,MRCPsych
Phone +35312493523
Email cfarren@stpatsmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol dependence poses a major problem for Irish and UK society, placing a huge burden on the health system. It is difficult to treat and relapse is common. There is an urgent need to develop novel treatment methods. One growing area of intervention is the use of mobile phone technology to develop personalised, patient-centred treatments. These can be used in outpatient settings, allowing patients to manage their own illness and take control of their recovery. In this study the investigators will investigate how a smartphone application, UControlDrink, can help alcoholics stay abstinent from alcohol. The application consists of a number of features known to aid recovery such as supportive messages and online therapy.


Description:

Alcohol use disorder (AUD) is a common and difficult disorder to treat. Only a fraction of sufferers seek treatment and the rate of relapse is high. There is therefore an urgent need for improved methods of promoting long term abstinence and recovery in AUD. This study will explore the effectiveness of a smartphone application, UControlDrink, in aiding recovery from AUD in patients who have been discharged from an inpatient alcohol treatment programme. The application comprises five recovery focused features:

supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, activities and trigger avoidance log, craving management and gamification. Patients will use the application for 3 months. A control group of patients will also be followed over the same time period. Cumulative abstinence duration as well as changes in questionnaire measures to baseline, time to first drink, proportion of patients continuously abstinent from alcohol, levels of activity within the app and patient satisfaction with their overall treatment will be measured at 3 months. If successful, this application may offer a unique, patient-centred, technology-driven, cost effective method of improving outcomes in AUD.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 30, 2018
Est. primary completion date July 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Patients will fulfil the criteria for an alcohol use disorder according to the Structured Clinical Interview for DSM-5 Axis I Disorders

2. Patients must complete an alcohol treatment programme at St. Patrick's University Hospital.

3. Primary addiction must be alcohol in poly-substance abusers.

4. Aged over 18 years of age and capable of providing written, informed consent.

5. Mini Mental State Examination (MSSE) score of =25.

6. Patients must have an iphone or Android smartphone and are familiar with using smartphone applications.

Exclusion Criteria:

1. Patients whose primary substance of abuse is not alcohol, although may meet the criteria for alcohol dependency/abuse.

2. Patients who do not have an iPhone or Android smartphone.

3. Age <18years or >70years.

4. Psychotic disorder

5. Patients who do not fully complete an inpatient treatment programme before discharge.

6. History of alcohol use disorder but not current.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
U Control Drink Smartphone Application
The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
Control group
The control group will receive treatment as usual.

Locations

Country Name City State
Ireland St. Patrick's University Hospital Dublin

Sponsors (1)

Lead Sponsor Collaborator
St Patrick's Hospital, Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of drinking days The number of drinking days will be assessed using the Time Line to Follow-Back scale (TLFB).The Alcohol TLFB is a descriptive questionnaire, using a calendar, participants will retrospectively record the number of days they drank over the previous 90 days. Drinking days will be calculated by summing the total number of days when alcohol was consumed in the previous 90 days. 3 months
Primary App activity score Activity score on the app 3 months
Primary Units of alcohol consumed per drinking day The Time Line Follow Back (TLFB) will be used to record the average number of units of alcohol consumed on drinking days. 3 months
Secondary Time to first drink Number of days to first drink 3 months
Secondary Changes in the Alcohol Use Disorders Identification Test scores from baseline Changes in scores on the Alcohol Use Disorders Identification Test between baseline and 3 month follow-up assessment. 3 months
Secondary Changes in the Alcohol Abstinence Self-Efficacy Scale scores from baseline Changes in the Alcohol Abstinence Self-Efficacy Scale scores between baseline and 3 month follow-up assessment. 3 months
Secondary Changes in the Obsessive Compulsive Drinking Scale scores from baseline Changes in scores on the Obsessive Compulsive Drinking Scale between baseline and 3 month follow-up assessment. 3 months
Secondary Changes in the Beck Depression Inventory scores from baseline Changes in scores on the Beck Depression Inventory between baseline and 3 month follow-up assessment. 3 months
Secondary Changes in the Beck Anxiety Inventory scores from baseline Changes in scores on the Beck Anxiety Inventory between baseline and 3 month follow-up assessment. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A
Completed NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Phase 2
Active, not recruiting NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Phase 2